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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to 
a combination of lutein and zeaxanthin and improved vision under bright 
light conditions pursuant to Article 13(5) of Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2,3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from DSM Nutritional Products and Kemin Foods, submitted for authorisation of a 
health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of France, 
the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the 
scientific substantiation of a health claim related to a combination of lutein and zeaxanthin and improved vision 
under bright light conditions. The Panel considers that the food is sufficiently characterised. Improved vision 
under bright light conditions is a beneficial physiological effect. The applicant provided a total of 10 published 
and one unpublished human intervention studies as being pertinent to the health claim. Five studies investigated 
the effects of lutein and/or zeaxanthin on macular pigment optical density, but did not assess vision, whereas two 
studies investigated the effects of lutein only. Two further studies had already been evaluated by the Panel in a 
previous assessment. No conclusions could be drawn from one further small (no effect) study. In a further trial 
with a large number of missing data owing to drop-out/non-compliance of study subjects, a combination of 
lutein and zeaxanthin had no effect on any outcomes of visual function in the population of subjects completing 
the protocol as planned. In weighing the evidence, the Panel took into account that the one study from which 
conclusions could be drawn did not show an effect of lutein plus zeaxanthin on vision. The Panel concludes that 
a cause and effect relationship has not been established between the consumption of a combination of lutein and 
zeaxanthin and improved vision under bright light conditions. 
© European Food Safety Authority, 2014 
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SUMMARY 
Following an application from DSM Nutritional Products and Kemin Foods, submitted for 
authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the 
Competent Authority of France, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 
was asked to deliver an opinion on the scientific substantiation of a health claim related to a 
combination of lutein and zeaxanthin and improved vision under bright light conditions. 
The scope of the application was proposed to fall under a health claim based on newly developed 
scientific evidence. The application included a request for the protection of proprietary data. 
The food that is the subject of the health claim is a combination of lutein and zeaxanthin. Lutein and 
zeaxanthin are xanthophyll carotenoids naturally present in food, especially in green leafy vegetables. 
Lutein and zeaxanthin can be measured in foods by established methods. The Panel considers that the 
food, a combination of lutein and zeaxanthin, which is the subject of the health claim is sufficiently 
characterised. 
The claimed effect relates to improved visual performance, in particular under bright light conditions. 
The target population proposed by the applicant is the general healthy population. The Panel considers 
that improved vision under bright light conditions is a beneficial physiological effect. 
The applicant provided a total of 10 published and one unpublished human intervention studies as 
being pertinent to the health claim.  
Five studies investigated the effects of lutein and/or zeaxanthin on macular pigment optical density, 
but did not assess vision, whereas two studies investigated the effects of lutein only, and not of the 
combination of lutein plus zeaxanthin that is the subject of the health claim, on visual outcomes. The 
Panel considers that no conclusions can be drawn from these studies for the scientific substantiation of 
the claim. 
Three published and one unpublished human intervention studies investigated the effects of lutein, 
either alone or in combination with zeaxanthin, on measures of vision. Two of these studies were 
already evaluated by the Panel in relation to a claim on lutein and maintenance of normal vision. The 
Panel considered that no conclusions could be drawn from these two studies for the scientific 
substantiation of the claim owing to important methodological limitations. 
In a randomised, single-blind, placebo-controlled, parallel study, 36 subjects were randomly assigned 
to consume daily for six months (i) 20 mg lutein and 2 mg zeaxanthin, (ii) 10 mg lutein, 2 mg 
zeaxanthin and 10 mg meso-zeaxanthin, or (iii) a placebo. The outcome measures included visual 
acuity, contrast sensitivity, glare disability and photostress recovery. No significant differences were 
observed between the lutein plus zeaxanthin group and the placebo group for any measure of vision. 
The Panel notes the small sample size of the study and considers that no conclusions can be drawn 
from this study for the scientific substantiation of the claim. 
In a randomised, double-blind, placebo-controlled, parallel trial, 115 subjects were randomised to 
consume daily for one year 10 mg lutein plus 2 mg zeaxanthin or a placebo. The primary outcome of 
the study, on which power calculations were based, was changes in macular pigment optical density. 
Secondary outcomes included measures of visual function, i.e. contrast sensitivity, glare 
sensitivity/tolerance and photostress recovery time. According to the statistical analysis plan, a 
repeated measures analysis of variance was foreseen to analyse the data. However, during a blind data 
review, the authors decided that a linear mixed model regression was more appropriate, owing to a 
“substantial number of unbalanced missing values”. In total, 34 subjects dropped out of the study. In 
the statistical analysis, the following three study populations were considered: (i) the “baseline set” 
(intention to treat, ITT); (ii) “intention to treat” (modified intention to treat, mITT); (iii) “protocol 
compliant” (per protocol, PP). When the ITT and mITT populations were considered, a significant 
improvement in contrast sensitivity and photostress recovery was reported in the lutein plus 
Combination of lutein and zeaxanthin and improved vision 
 
 
EFSA Journal 2014;12(7):3753 3 
zeaxanthin group compared with the placebo group, whereas no significant changes between groups 
were observed for glare sensitivity. No significant differences were observed between groups for 
contrast sensitivity, photostress recovery or glare sensitivity when the analysis was performed in the 
PP population. The Panel notes that a combination of lutein and zeaxanthin had no effect on any 
outcomes of visual function in the population of subjects completing the protocol as planned (i.e. PP 
population), that at least 50 % of the subjects considered for the ITT and the mITT analyses had 
missing data owing to drop-out/non-compliance of study subjects, and that no evidence was provided 
that could justify the discrepancy of the results obtained from the different analyses. The Panel also 
notes that the statistical analysis was not carried out according to the statistical analysis plan, that 
measures of visual function were secondary outcomes in this study and that multiplicity of outcomes 
was not considered in the statistical analyses. The Panel considers that this study does not show an 
effect of a combination of lutein and zeaxanthin on vision. 
In weighing the evidence, the Panel took into account that the one study from which conclusions could 
be drawn did not show an effect of lutein plus zeaxanthin on vision. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of a combination of lutein and zeaxanthin and improved vision under bright light 
conditions. 
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BACKGROUND 
Regulation (EC) No 1924/2006
4
 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of this 
Regulation, are authorised in accordance with this Regulation, and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Article 13(5) of this 
Regulation lays down provisions for the addition of claims (other than those referring to the reduction 
of disease risk and to children’s development and health) which are based on newly developed 
scientific evidence, or which include a request for the protection of proprietary data, to the Community 
list of permitted claims referred to in Article 13(3). 
According to Article 18 of this Regulation, an application for inclusion in the Community list of 
permitted claims referred to in Article 13(3) shall be submitted by the applicant to the national 
competent authority of a Member State, which will make the application and any supplementary 
information supplied by the applicant available to the European Food Safety Authority (EFSA). 
STEPS TAKEN BY EFSA 
 The application was received on 29/10/2013. 
 The scope of the application was proposed to fall under a health claim based on newly 
developed scientific evidence. The application included a request for the protection of 
proprietary data. 
 The scientific evaluation procedure started on 11/12/2013. 
 On 05/03/2014, the Working Group on Claims of the NDA Panel agreed on a list of questions 
for the applicant to provide additional information to accompany the application. The clock 
was stopped on 25/03/2014 and was restarted on 09/04/2014, in compliance with Article 18(3) 
of Regulation (EC) No 1924/2006. 
 On 11/04/2014, EFSA received the requested information (which was made available to 
EFSA in electronic format on 08/04/2014). 
 During its meeting on 25/06/2014, the NDA Panel, having evaluated the data submitted, 
adopted an opinion on the scientific substantiation of a health claim related to a combination 
of lutein and zeaxanthin and improved vision under bright light conditions. 
TERMS OF REFERENCE 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with 
Article 16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an 
opinion on the scientific substantiation of a health claim related to: a combination of lutein and 
zeaxanthin and improved vision under bright light conditions. 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation for the marketing 
of a combination of lutein and zeaxanthin, a positive assessment of its safety, nor a decision on 
whether a combination of lutein and zeaxanthin is, or is not, classified as a foodstuff. It should be 
noted that such an assessment is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006. 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicants’ names and addresses 
DSM Nutritional Products France, Le Véronèse, 19/21 Avenue Dubonnet, 92400 Courbevoie, France. 
Kemin Foods, L.C., Campo Grande, 35-8° D, 1700-087 Lisboa, Portugal. 
The application includes a request for the protection of proprietary data for one unpublished study 
(DSM Nutritional Products Ltd and Kemin Foods L.C., 2013), in accordance with Article 21 of 
Regulation (EC) No 1924/2006. 
Food/constituent as stated by the applicant 
According to the applicant, the food that is the subject of the health claim is a combination of lutein 
and zeaxanthin. 
Health relationship as claimed by the applicant 
According to the applicant, the consumption of lutein together with zeaxanthin leads to an increase in 
macular pigment optical density, which, in turn, is claimed to improve visual performance, in 
particular under bright light conditions. The applicant indicated that the improved visual performance 
is brought about, and can be measured, by a faster recovery from photo bleaching, higher tolerance 
against the “veiling effect” of glare and improved contrast sensitivity in a high luminance field of 
view. 
Wording of the health claim as proposed by the applicant 
The applicant has proposed the following wording for the health claim: “Lutein together with 
zeaxanthin helps maintain clarity and contrast of sight in bright light conditions”. 
Specific conditions of use as proposed by the applicant 
The applicant has proposed an intake of 10 mg lutein plus 2 mg zeaxanthin per day. The proposed 
target population is the general healthy population. 
ASSESSMENT 
1. Characterisation of the food/constituent 
The food that is the subject of the health claim is a combination of lutein and zeaxanthin. 
Lutein and zeaxanthin are xanthophyll carotenoids naturally present in food, especially in green leafy 
vegetables such as spinach and kale. Lutein and zeaxanthin can be measured in foods by established 
methods. 
The applicant indicated the Chemical Abstracts Service (CAS) numbers for both lutein (127-40-2) and 
zeaxanthin (144-68-3) and provided monographs (JECFA, 2004, 2006) which the ingredients comply 
with. 
An overview of the manufacturing process and information regarding stability and reproducibility of 
batches were provided. The applicant also submitted two bioavailability studies (Hartmann et al., 
2004; Evans et al., 2013) on the formulations of the lutein and zeaxanthin used in the human study 
(DSM Nutritional Products Ltd and Kemin Foods L.C., 2013, unpublished) claimed as proprietary by 
the applicant. 
The Panel considers that the food, a combination of lutein and zeaxanthin, which is the subject of the 
health claim, is sufficiently characterised. 
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2. Relevance of the claimed effect to human health 
The claimed effect relates to improved visual performance, in particular under bright light conditions. 
The target population proposed by the applicant is the general healthy population. 
Vision is a defined function of the eye and nervous system. An increase in vision, maintenance of 
vision or reduced loss of vision is a beneficial physiological effect for the general population. Visual 
function can be measured by using standard tests of visual acuity and contrast sensitivity under 
specific light conditions, e.g. under bright light conditions. 
Changes in macular pigment optical density (MPOD) have been proposed as outcome measures for the 
scientific substantiation of claims on the maintenance of vision. To this end, the applicant provided 
four observational studies which reported on the relationship between MPOD and photophobia light 
threshold (Wenzel et al., 2006), heterochromatic luminance contrast (Renzi and Hammond, 2010), 
photostress recovery, glare disability and visual discomfort (Stringham et al., 2011), and photostress 
recovery, glare disability and chromatic contrast (Hammond et al., 2013). The Panel notes that MPOD 
is not a measure of visual function and considers that the available evidence (including the four 
observational studies provided by the applicant) does not establish that changes in MPOD predict 
changes in visual function. Therefore, the Panel considers that MPOD is not a suitable outcome 
measure for the scientific substantiation of claims related to increased vision, maintenance of vision or 
reduced loss of vision (EFSA NDA Panel, 2012b). 
The Panel considers that improved vision under bright light conditions is a beneficial physiological 
effect. 
3. Scientific substantiation of the claimed effect 
A claim on lutein in combination with zeaxanthin and maintenance of normal vision has already been 
assessed by the Panel with an unfavourable outcome (EFSA NDA Panel, 2011). 
The applicant performed a literature search in PubMed using the search terms (“lutein” or 
“zeaxanthin”) and (“macular pigment” or “vision”) restricted to “humans”, and (“lutein” or 
“zeaxanthin”) restricted to “clinical trial”. The search was carried out on 20 December 2012, with an 
update for studies published thereafter until 20 July 2013. Only studies carried out in healthy 
populations were included. Studies which were concerned with MPOD in relation to neuronal 
processing were excluded. 
The applicant provided a total of 10 published human intervention studies and one unpublished human 
intervention study as being pertinent to the health claim. 
Five studies investigated the effects of lutein and/or zeaxanthin on MPOD, but did not assess vision 
(Schalch et al., 2007; Johnson et al., 2008; Bone and Landrum, 2010; Graydon et al., 2012; Landrum 
et al., 2012), whereas two studies (Ma et al., 2009; Yao et al., 2013) investigated the effects of lutein 
only, and not of the combination of lutein plus zeaxanthin that is the subject of the health claim, on 
visual outcomes. The Panel considers that no conclusions can be drawn from these studies for the 
scientific substantiation of the claim. 
Three published human intervention studies (Kvansakul et al., 2006; Rodriguez-Carmona et al., 2006; 
Loughman et al., 2012) and one unpublished human intervention study (DSM Nutritional Products Ltd 
and Kemin Foods L.C., 2013) investigated the effects of lutein, either alone or in combination with 
zeaxanthin, on measures of vision. Two of these studies (Kvansakul et al., 2006; Rodriguez-Carmona 
et al., 2006) were already evaluated by the Panel in relation to a claim on lutein and maintenance of 
normal vision (EFSA NDA Panel, 2012a). The Panel considered that no conclusions could be drawn 
from these two studies for the scientific substantiation of the claim owing to important methodological 
limitations. 
Combination of lutein and zeaxanthin and improved vision 
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In a randomised, single-blind, placebo-controlled, parallel study (Loughman et al., 2012), 36 subjects 
(19 male, 17 female, mean age 51 ± 13 years) were randomly assigned to consume daily for six 
months (i) 20 mg lutein and 2 mg zeaxanthin (n = 12), (ii) 10 mg lutein, 2 mg zeaxanthin and 10 mg 
meso-zeaxanthin (n = 12) or (iii) a placebo (n = 12). The outcome measures, which were assessed at 
baseline and at months 3 and 6, included visual acuity, contrast sensitivity, glare disability, photostress 
recovery, ocular stray light, MPOD and serum concentrations of lutein and total carotenoids. Four 
subjects dropped out of the study. Between-group comparisons were carried out with a repeated 
measures analysis of variance (RM-ANOVA) followed by Tukey’s test. No significant differences 
were observed between the lutein plus zeaxanthin group and the placebo group for any measure of 
vision. It was indicated in the publication that “this exploratory study had adequate statistical power to 
detect only large within-group or between group differences”. The Panel notes the small sample size 
of the study and that post-hoc power calculations indicated that the study was underpowered. The 
Panel considers that no conclusions can be drawn from this study for the scientific substantiation of 
the claim. 
In a randomised, double-blind, placebo-controlled, parallel trial (DSM Nutritional Products and Kemin 
Foods, 2013, unpublished; claimed as proprietary by the applicant), 115 subjects (67 female, 48 male) 
recruited from the University of Georgia (USA) were randomised to consume daily for one year 10 mg 
lutein plus 2 mg zeaxanthin (n = 57) or a placebo (cellulose; n = 58). Subjects were included if they 
were healthy, between 18 and 40 years and had a body mass index (BMI) of 20-30 kg/m
2
. Smokers 
were excluded from the study. The participants were asked to abstain from eating dark-green leafy 
vegetables and all other sources with high xanthophyll content during the whole study period. No 
information on the compliance with this requirement was provided. No assessment of the background 
diet was performed. The study was approved by the Institutional Review Board at the University of 
Georgia. The primary outcome of the study, on which power calculations were based, was changes in 
MPOD. Secondary outcomes were serum xanthophyll concentrations and measures of visual function, 
i.e. contrast sensitivity, glare sensitivity/tolerance and photostress recovery time. The outcomes were 
measured at baseline and at months 3, 6, 9 and 12. According to the statistical analysis plan, a RM-
ANOVA was foreseen to analyse the data. However, during a blind data review, the authors decided 
that a linear mixed model regression was more appropriate, owing to a “substantial number of 
unbalanced missing values”. In total, 34 subjects dropped out of the study. In the statistical analysis, 
the following three study populations were considered: (i) the “baseline set” (intention to treat, ITT), 
i.e. all subjects who were randomised (n = 115); (ii) “intention to treat” (modified intention to treat, 
mITT), defined by the applicant as all subjects who participated at baseline and had at least one 
subsequent visit (n = 109); (iii) “protocol compliant” (per protocol, PP), defined by the applicant as all 
randomised subjects who had complete data sets for all visual measurements and who were at least 
80 % compliant with the study products (n = 55). When the ITT and mITT populations were 
considered, a significant improvement in contrast sensitivity (p = 0.028 and p = 0.030 for the ITT and 
mITT, respectively) and photostress recovery (p = 0.015 and p = 0.013, respectively) was reported in 
the lutein plus zeaxanthin group compared with the placebo group, whereas no significant changes 
between groups were observed for glare sensitivity. No significant differences were observed between 
groups for contrast sensitivity, photostress recovery or glare sensitivity when the analysis was 
performed in the PP population (p = 0.75, p = 0.48 and p = 0.85, respectively). Upon EFSA’s request 
for clarification on the discrepancy of the results between the ITT and mITT populations and the PP 
population, the applicant argued that the absence of significant effects of the intervention on outcomes 
of visual function in the PP population could be the result of “(i) a loss of power in the per protocol 
subgroup, (ii) random differences between the per protocol population and the other subjects or (iii) a 
systematic bias between the per protocol population and the other subjects”. The Panel considers that 
the absence of significant effects in the PP population could not be explained by a lack of power and 
notes that no evidence was provided to indicate that random differences or a systematic bias could 
explain the absence of effects in the PP population. The Panel notes that a combination of lutein and 
zeaxanthin had no effect on any outcomes of visual function in the population of subjects completing 
the protocol as planned (i.e. PP population), that at least 50 % of the subjects considered for the ITT 
and the mITT analyses had missing data or were not compliant with the protocol, and that no evidence 
was provided that could justify the discrepancy of the results obtained from the different analyses. The 
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Panel also notes that the statistical analysis was not carried out in accordance with the statistical 
analysis plan, that measures of visual function were secondary outcomes in this study and that 
multiplicity of outcomes was not considered in the statistical analyses. The Panel considers that this 
study does not show an effect of a combination of lutein and zeaxanthin on vision. 
In weighing the evidence, the Panel took into account that the one study from which conclusions could 
be drawn did not show an effect of lutein plus zeaxanthin on vision. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of a combination of lutein and zeaxanthin and improved vision under bright light 
conditions. 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
 The food, a combination of lutein and zeaxanthin, which is the subject of the health claim, is 
sufficiently characterised. 
 The claimed effect relates to improved visual performance, in particular under bright light 
conditions. The target population proposed by the applicant is the general healthy population. 
Improved vision under bright light conditions is a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of a 
combination of lutein and zeaxanthin and improved vision under bright light conditions. 
DOCUMENTATION PROVIDED TO EFSA 
Health claim application on a combination of lutein and zeaxanthin and improved vision under bright 
light conditions pursuant to Article 13(5) of Regulation (EC) No 1924/2006 (Claim serial No: 
0399_FR). October 2013. Submitted by DSM Nutritional Products Ltd and Kemin Foods. 
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ABBREVIATIONS 
BMI   body mass index 
CAS   Chemical Abstracts Service 
ITT   intention to treat 
mITT   modified intention to treat 
MPOD   macular pigment optical density 
PP   per protocol 
RM-ANOVA  repeated measures analysis of variance 
